Skip to main content
. 2018;19(2):435–441. doi: 10.22034/APJCP.2018.19.2.435

Table 2.

Correlations between Clinicopathological Parameters or Expression Levels of CTR1 and TS and Tumor Response in NSCLC Patients Treated with S-1/carboplatin Doublet Chemotherapy

Variables na Good response (%) Poor response (%) P value
Age <65 8 5 (63) 3 (78) 0.08
≥65 20 5 (25) 15 (75)
Sex Male 18 8 (44) 10 (56) 0.41
Female 10 2 (20) 8 (80)
Tumor histology Adenocarcinoma 6 2 (33) 4 (67) 1.00
Non-adenocarcinoma 22 8 (36) 14 (64)
Clinical stage III 7 4 (57) 3 (43) 0.19
IV 21 6 (29) 15 (71)
Performance status 0/1 26 10 (38) 16 (62) 0.53
2 2 0 (0) 2 (100)
Smoking status Never 4 0 (0) 4 (100) 0.27
Ever 24 10 (42) 14 (58)
CTR1 High 11 7 (64) 4 (36) 0.02b
Low 17 3 (18) 14 (82)
TS High 15 3 (20) 12 (80) 0.06
Low 13 7 (54) 6 (46)
CTR1/TS Either CTR1High or TSLow 20 10 (50) 10 (50) 0.01b
Both CTR1Lowand TSHigh 8 0 (0) 8 (100)
a

Tumor response was evaluable in 28 of the 29 patients;

b

Statistically significant; CTR1, copper transporter 1; NSCLC, non-small cell lung cancer; TS, thymidylate synthase